Edition:
United States

Akcea Therapeutics Inc (AKCA.OQ)

AKCA.OQ on NASDAQ Stock Exchange Global Select Market

19.15USD
14 Dec 2017
Change (% chg)

$-0.05 (-0.26%)
Prev Close
$19.20
Open
$19.09
Day's High
$19.88
Day's Low
$18.58
Volume
176,699
Avg. Vol
112,582
52-wk High
$31.23
52-wk Low
$8.10

Summary

Name Age Since Current Position

Stanley Crooke

72 Chairman of the Board

Paula Soteropoulos

49 2015 President, Chief Executive Officer, Director

Michael Maclean

52 2017 Chief Financial Officer

Jeffrey Goldberg

44 2015 Chief Operating Officer

Elizabeth Hougen

55 2017 Senior Vice President - Finance

Louis O'Dea

66 2016 Chief Medical Officer

B. Lynne Parshall

63 2015 Director

Edward Fitzgerald

62 2017 Independent Director

Christopher Gabrieli

57 2016 Independent Director

Elaine Hochberg

59 2017 Independent Director

Sandford Smith

70 2017 Independent Director

Biographies

Name Description

Stanley Crooke

Dr. Stanley T. Crooke, M.D. Ph.D., serves as Chairman of the Board of the Company. Dr. Crooke has served as a member of our board of directors since January 2015. Dr. Crooke is a founder of Ionis and has been Chief Executive Officer and a Director since January 1989. He was elected Chairman of Ionis' board of directors in February 1991. Prior to founding Ionis, from 1980 until January 1989, Dr. Crooke was employed by SmithKline Beckman Corporation, a pharmaceutical company, where his titles included President of Research and Development of SmithKline and French Laboratories. He is currently a member of the board of directors of BIO, a biotechnology industry association. He is the named inventor on some of the key patents in the field of RNA-targeted therapeutics, and has over 30 years of drug discovery and development experience. Our board of directors believes Dr. Crooke is uniquely suited to serve on our board of directors primarily because, as the Chief Executive Officer and founder of Ionis, he has dedicated over 26 years to discovering and developing Ionis' antisense technology platform.

Paula Soteropoulos

Ms. Paula Soteropoulos serves as President, Chief Executive Officer, Director of the Company. Ms. Soteropoulos joined Akcea as President and Chief Executive Officer and as a member of our board of directors in January 2015. Prior to joining Akcea, Ms. Soteropoulos was a member of the executive leadership team of Moderna Therapeutics Inc., a private biotechnology company, serving as the Cardiometabolic Business Unit General Manager and Senior Vice President of Strategic Alliances from July 2013 to December 2014. Prior to Moderna, Ms. Soteropoulos spent 21 years at Genzyme Corporation in various leadership positions driving strategy, sales and marketing, business development, manufacturing process development, strategic capacity planning, and supply chain development. Since July 2013, Ms. Soteropoulos has served on the supervisory board of uniQure N.V., a public biotechnology company. Ms. Soteropoulos also serves on the advisory board of the Tufts University Chemical and Biological Engineering Department.

Michael Maclean

Mr. Michael Maclean is Chief Financial Officer of the company. He was Chief Financial Officer, Executive Vice President, at PureTech Health, plc, a biotech company, since September 2015. From July 2014 to June 2015, Mr. MacLean was Chief Financial Officer, North America at Iron Mountain and from October 2012 to June 2014 he was Senior Vice President, Worldwide Controller at Iron Mountain. In addition, Mr. MacLean previously served as senior vice president of finance and chief accounting officer of Biogen Inc. where he led Biogen’s worldwide finance organization, as well as evaluated financial implications of commercial, R&D and other expansion strategies.

Jeffrey Goldberg

Mr. Jeffrey M. Goldber serves as Chief Operating Officer of the Company. Mr. Goldberg joined Akcea as Chief Operating Officer in January 2015. Prior to joining Akcea, from December 2012 to September 2014, Mr. Goldberg was a member of the executive leadership team at Proteostasis Therapeutics, Inc., a now public biotechnology company focusing on neurology and orphan diseases, where he served as Vice President of Business Operations. Prior to that, Mr. Goldberg spent over 11 years in positions of increasing responsibility with Genzyme and Sanofi S.A., most recently as Associate Vice President, Project Head, within Sanofi Oncology.

Elizabeth Hougen

Ms. Elizabeth L. Hougen is Senior Vice President - Finance of the Company. Ms. Hougen has served as Chief Financial Officer to Akcea since January 2015 under the services agreement between Akcea and Ionis. Ms. Hougen has served as Senior Vice President, Finance and Chief Financial Officer of Ionis since January 2013 and currently serves in this role. From January 2007 to December 2012, Ms. Hougen served as Ionis' Vice President, Finance and Chief Accounting Officer, and from May 2000 to January 2007, she served as Ionis' Vice President, Finance. Prior to joining Ionis in 2000, Ms. Hougen was Executive Director, Finance and Chief Financial Officer for Molecular Biosystems, Inc., a public biotechnology company.

Louis O'Dea

Dr. Louis St. L. O'Dea, MB BCh BAO. FRCP(C), serves as Chief Medical Officer of the Company. Dr. O'Dea joined Akcea as Chief Medical Officer in January 2016. Prior to joining Akcea, Dr. O'Dea was Chief Medical Officer at Oxford Immunotec Global PLC, a private diagnostics company, from June 2014 to January 2016, overseeing medical affairs and clinical development. Prior to Oxford, Dr. O'Dea was Chief Medical Officer and Head of Regulatory Affairs at Moderna from January 2012 to June 2014. Before Moderna, Dr. O'Dea had positions including Chief Medical Officer at Radius Health, Inc., a public biopharmaceuticals company, an academic position at McGill University, and worldwide Head of Clinical Development for Endocrine and Metabolic products at Serono.

B. Lynne Parshall

Ms. B. Lynne Parshall, J.D., serves as Director of the Company. Ms. Parshall has served as a member of our board of directors since January 2015. Ms. Parshall has served as a Director of Ionis since September 2000. She has been the Ionis Chief Operating Officer since December 2007 and previously served as the Chief Financial Officer from June 1994 to December 2012. She also served as the Ionis Corporate Secretary through 2014 and has served in various executive roles since November 1991. Prior to joining Ionis, Ms. Parshall practiced law at Cooley LLP, outside counsel to Ionis and Akcea, where she was a partner from 1986 to 1991. Ms. Parshall is currently a member of the board of directors of Cytokinetics Inc., a public biopharmaceutical company. She was a member of the board of directors of Regulus Therapeutics Inc., a public biopharmaceutical company, from January 2009 to June 2015. She is also a member of the American, California and San Diego bar associations. In addition, Ms. Parshall has over 30 years of experience structuring and negotiating strategic licensing and financing transactions in the life sciences field. Our board of directors believes Ms. Parshall is uniquely suited to serve on our board of directors primarily because, as the Chief Operating Officer and an executive of Ionis for over 20 years, she has valuable experience and expertise.

Edward Fitzgerald

Mr. Edward M. Fitzgerald serves as Independent Director of the Company. Mr. Fitzgerald has served as a member of our board of directors since May 2017. He has been an independent business advisor since April 2016. From June 2010 to April 2016, Mr. Fitzgerald served as Executive Vice President, Chief Financial Officer and Treasurer of ARIAD Pharmaceuticals, Inc., an international biopharmaceutical company, and was its Senior Vice President, Chief Financial Officer and Treasurer from May 2002 to June 2010. He was Senior Vice President, Chief Financial Officer and Secretary of AltaRex, Inc., a development stage biotechnology company, from 1998 to April 2002. He held management positions at BankBoston Corporation from 1992 to 1997 in its Mergers & Acquisitions Group and its Consumer Lending Group. He was a partner in the Audit and Business Advisory Practice of Arthur Andersen & Co. from 1989 to 1992.

Christopher Gabrieli

Dr. Christopher Gabrieli, M.D., serves as Independent Director of the Company. Mr. Gabrieli has served as a member of our board of directors since April 2016. Since June 2014, Mr. Gabrieli has served as Chief Executive Officer of Empower Schools, a non-profit education innovation organization, and since May 2014, Mr. Gabrieli has served as a Partner Emeritus at Bessemer Venture Partners, a venture capital fund. Previously, from 1987 to April 2014, Mr. Gabrieli was a Partner at Bessemer, where he led their life sciences practice and made a founding investment in Ionis. Mr. Gabrieli served on Ionis' board of directors from 1989 to 2006. During his time at Bessemer, he invested in over thirty life science and health care companies, including several that became publicly traded. Mr. Gabrieli is also the Chairman of the Massachusetts Board of Higher Education and a part-time Lecturer at the Harvard Graduate School of Education.

Elaine Hochberg

Ms. Elaine Hochberg serves as Independent Director of the Company. Ms. Hochberg has served as a member of our board of directors since March 2017. Currently, Ms. Hochberg is a managing partner of Elaran, LLC, a business strategy and management firm. Ms. Hochberg served in various senior leadership positions at Forest Laboratories, Inc. from June 1997 to June 2014 when the company was sold to Actavis. Her positions included Executive Vice President, International, Strategic Planning and Government Affairs from December 2013 to June 2014, Executive Vice President, US Sales and Marketing, Chief Commercial Officer from 2010 to November 2013, Senior Vice President, Marketing, Chief Commercial Officer, from 2007 to 2010, Senior Vice President, Marketing from 1999 to 2007 and Vice President, Marketing from 1997 to 1999. Ms. Hochberg began her pharmaceutical career in July of 1985 at Sandoz Pharmaceuticals (now Novartis). In April of 1991, she joined Wyeth-Ayerst Laboratories (now Pfizer) where she held several positions of increasing responsibility, ultimately serving as Assistant Vice-President, Marketing of the company's Vaccines and Pediatrics division. She also serves on the boards of several nonprofit organizations in the New York City area. Our board of directors believes that Ms. Hochberg is uniquely suited to serve on our board of directors because of her over 30 years of experience leading commercial organizations for life science companies.

Sandford Smith

Mr. Sandford ("Sandy") D. Smith serves as Independent Director of the Company. Mr. Smith has served as a member of our board of directors since March 15, 2017. For the past 20 years, he has focused on drugs and therapies for rare genetic diseases. Since December 2011, Mr. Smith has served as Founder and Chairman of Global Biolink Partners, a consulting firm advising public biopharmaceutical companies on commercial strategy and international business models. From July 2015 to January 2016, Mr. Smith served as interim Chief Executive Officer of Aegerion Pharmaceuticals, Inc., a biotechnology company, and following Aegerion's merger with Novelion Therapeutics, Inc., he served as Novelion's Vice Chair until March 2017. From 1996 to 2011, Mr. Smith held various positions at Sanofi-Genzyme (formerly Genzyme Corporation), most recently leading the integration of Genzyme's international business into Sanofi's global organization. Prior to that, he served as Executive Vice President of Genzyme Corporation, and President of Genzyme International. From 1986 to 1996, Mr. Smith was President, Chief Executive Officer and a member of the Board of Directors of RepliGen Corporation. From 1977 to 1985, Mr. Smith held various positions at Bristol-Myers Squibb, most recently serving as Vice President of Business Development and Strategic Planning for the Pharmaceutical and Nutritional Division. He currently serves on the boards of Cytokinetics Inc., Apricus Biosciences and Neuralstem Inc., each a publicly traded biopharmaceutical company.